Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 3 1

Status

Unknown 5Recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Colorectal Neoplasms 3978Pancreatic Neoplasms 2479Carcinoma, Hepatocellular 2413Stomach Neoplasms 2109Rectal Neoplasms 1676Colonic Neoplasms 1629Esophageal Neoplasms 1312Liver Neoplasms 878Neoplasms 633Breast Neoplasms 596Cholangiocarcinoma 525Gastrointestinal Neoplasms 468Neoplasm Metastasis 456Esophageal Squamous Cell Carcinoma 434Lung Neoplasms 422Biliary Tract Neoplasms 277Prostatic Neoplasms 270Ovarian Neoplasms 235Barrett Esophagus 224Adenocarcinoma Of Esophagus 202Gallbladder Neoplasms 191Head and Neck Neoplasms 185Carcinoma, Non-Small-Cell Lung 185Gastrointestinal Stromal Tumors 180Anus Neoplasms 179Recurrence 168Melanoma 162Adenocarcinoma 156Uterine Cervical Neoplasms 153Bile Duct Neoplasms 153

Interventions

Oxaliplatin 2Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Cancer × Gastrointestinal × Clear all
NCT06387810 2024-07-10

undetermined

Peking Union Medical College Hospital

Phase 2 Recruiting
45 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT04855331 2023-05-09

Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC

Fudan University

Phase NA Unknown
120 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT04617821 2022-01-28

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Fudan University

Phase 3 Unknown
300 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT02717091 2020-09-10

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Nagoya University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

NCT03850769 2020-03-10

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡